Vancouver, British Columbia, September 7, 2007 – Protox Therapeutics Inc. (TSX-V:PRX) today announced that interim data from the recently completed Phase 1 clinical study testing PRX302 in patients with locally recurrent prostate cancer following radiation failure will be presented at the American Urological Association (“AUA”) South Central Section Annual Meeting. The conference will take place at the Broadmoor Hotel in Colarado Springs, Colarado.
